Search

Displaying results 1081 - 1090 of 4437 in total
  1. Drug

    Mefenamic acid

    go.drugbank.com/drugs/DB00784
    Approved

    A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.

    Mixtures: MEFA SUSPENSION 50MG/5MLProducts: DYFENAMIC PAEDIATRIC SUSPENSION 50MG/5ML
  2. Drug

    Levallorphan

    go.drugbank.com/drugs/DB00504
    Approved

    It should be used cautiously; levallorphan reverses severe opioid-induced respiratory depression but may exacerbate respiratory depression such as that induced by alcohol or other non-opioid central depressants

  3. Drug

    Levamlodipine

    go.drugbank.com/drugs/DB09237
    ApprovedInvestigational

    [L10833] As a racemic mixture, amlodipine contains (R) and (S)-amlodipine isomers, but only (S)-amlodipine as the active moiety possesses therapeutic activity.

    Mixtures: ALENCAL IRBE 5/300MG TABLETAS RECUBIERTAS, ALENCAL VALS 2.5/160MG TABLETAS RECUBIERTAS
  4. Drug

    Ublituximab

    go.drugbank.com/drugs/DB11850
    ApprovedInvestigational

    [A244210, A244215,A241045] Ublituximab was initially developed by LFB Group but was licensed to TG Therapeutics in 2012. … CD20, an antigen expressed by various B and T cells, is an attractive therapeutic target in various cancers and autoimmune conditions.

  5. Drug

    Voxilaprevir

    go.drugbank.com/drugs/DB12026
    ApprovedInvestigational

    By inhibiting viral protease NS3/4A, voxilaprevir therefore prevents viral replication and function. … Voxilaprevir exerts its antiviral action by reversibly binding and inhibiting the NS3/4A serine protease of Hepatitis C Virus (HCV) [FDA Label].

    Mixtures: VOSEVI FILM-COATED TABLETS 400MG/100MG/100MG
  6. Drug

    Sotrovimab

    go.drugbank.com/drugs/DB16355
    ApprovedInvestigational

    [L34425, L34430, L34440] However, in April 2022, the FDA removed the EUA for sotrovimab due to the rising COVID-19 cases caused by the Omicron BA.2 sub-variant, where the drug is ineffective.

  7. Drug

    Oxamniquine

    go.drugbank.com/drugs/DB01096
    Approved

    An anthelmintic with schistosomicidal activity against Schistosoma mansoni, but not against other Schistosoma spp. … Oxamniquine causes worms to shift from the mesenteric veins to the liver where the male worms are retained; the female worms return to the mesentery, but can no longer release eggs.

  8. Drug

    Neomycin

    go.drugbank.com/drugs/DB00994
    ApprovedInvestigationalVet approved

    [A175042] Neomycin is active against both gram-positive and gram-negative organisms and mediates its pharmacological action by binding to bacterial ribosomes and inhibiting protein synthesis, which is … also used in combination with [polymyxin B] sulfates and [hydrocortisone] in otic suspensions for use in the treatment of bacterial infections in the external auditory canal, including infections caused by

    Mixtures: Bus and Classroom Yellow, Care Bus and Classroom Yellow
  9. Drug

    Isometheptene

    go.drugbank.com/drugs/DB06706
    Approved

    Isometheptene is a sympathomimetic drug that causes vasoconstriction. It is used for treating migraines and tension headaches.

    Mixtures: DIPIRONA SODICA / ISOMETEPTENO MUCATO/CAFEINA 300 MG / 30 MG/30MG TABLETA RECUBIERTA
  10. Drug

    Flibanserin

    go.drugbank.com/drugs/DB04908
    ApprovedInvestigational

    It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder drug by Sprout Pharmaceuticals … In February of 2018 Flibanserin was approved by Health Canada under the brand name Addyi for a similar indication as approved by the FDA.